Skip to main content
OpenTrials
Completed

NCT Number: NCT05586789

A Study of the Efficacy and Safety of Ranquilon Tablets in Patients With Anxiety in Neurasthenia and Adjustment Disorders

The primary objective of the study is to evaluate the efficacy of Ranquilon, 1 mg tablets, at a dose of 6 mg/day compared to placebo for the treatment of patients with anxiety in neurasthenia and adjustment disorder.

An additional study objective was to evaluate the safety of Ranquilon, 1 mg tablets, at a dose of 6 mg/day compared to placebo in patients with anxiety in neurasthenia and adjustment disorder.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Anxiety Adjustment Disorders Anxiety Disorders Mental Disorders Neurasthenia Somatoform Disorders Trauma and Stressor Related Disorders

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Engels Psychiatric Hospital State Health Care Institution of the Ministry of Health of the Saratov Region, Engel's, Russia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men and women between the ages of 18 and 70
  • Presence of written consent to participate in the study in accordance with applicable law
  • Patients with anxiety and diagnoses based on ICD-10 criteria: neurasthenia (F48.0) or adjustment disorder (F43.2)
  • HARS anxiety scores of 18-24
  • Severity of asthenia on the Asthenia Self Assessment Scale (MFI-20) of more than 50 points
  • Hamilton Depression Assessment Scale (HAMD-17) score < 6
  • CGI-s scale score of at least 4
  • Negative pregnancy test for women of preserved reproductive potential
  • Consent to use effective contraception for the duration of the study and 30 days after completion (for women of unresolved reproductive potential and men)
  • Ability to understand the requirements for study participants, to give written consent to participate in the study (including the use and communication of patient health information relevant to the study) and to comply with the procedures of the study protocol

Exclusion criteria

  • Known intolerance to the active ingredient and/or excipients in the study drug/placebo of the study drug
  • Known presence of lactase deficiency, lactose intolerance, glucose-galactose malabsorption or galactose intolerance
  • Patients who require concomitant therapy prohibited in this study (MAO inhibitors, antidepressants, neuroleptics, anxiolytics and sedatives (including herbal), sleeping pills when used on a continuous basis), or have taken these drugs within the last month
  • Established or suspected alcohol/drug use at the time of screening or randomization, and/or a history of alcohol, drug or drug dependence
  • Presence of cancer, including a history of cancer (with the exception of a cured tumor with sustained remission for more than 5 years)
  • Presence of tuberculosis, including a history of tuberculosis
  • The presence of HIV, chronic viral hepatitis B/C, syphilis (including a history), or a positive test for HIV, hepatitis B/C, syphilis at screening
  • Patients with a diagnosis established on the basis of ICD-10 criteria: other anxiety disorders (F41)
  • Schizophrenia, schizoaffective, affective and panic disorders
  • Acute psychosis (endogenous-procedural, organic or somatogenic), including history
  • Organic lesions of the central nervous system of traumatic and alcoholic genesis
  • Postencephalitic syndrome
  • Brain tumors, including in the anamnesis
  • Degenerative diseases of the central nervous system (CNS), in particular, multiple sclerosis
  • Depression, including a history of depression
  • Generalized anxiety disorder, including a history
  • Suicidal thoughts or ideas; a history of suicide attempts
  • Epilepsy, seizures, including a history of seizures
  • Diabetes mellitus at the stage of decompensation
  • Established diagnosis of chronic kidney disease stage 3A or higher, or glomerular filtration rate (GFR) calculated by the Cockcroft-Gault formula = 59 ml/min/1.73 m2 or less
  • Established diagnosis of hepatic failure of any severity, or elevated ALT, AST or total bilirubin, urea >3 times the upper limit of normal values
  • Conditions after major surgical interventions, if less than six months have elapsed since the intervention
  • Chronic heart failure New York Heart Association (NYHA) functional class III-IV
  • Severe, decompensated, or unstable disease (any disease or condition that threatens the patient's life or worsens the patient's prognosis, or makes it impossible to perform a clinical trial in the patient)
  • Pregnant women, women breastfeeding, or women planning to become pregnant during the study and 30 days after study participation ends
  • Refusal by the patient to use approved contraception or to completely abstain from sexual intercourse during the entire period of study participation, beginning at Visit 0, and for 30 days after completion of study participation
  • Patient's current or planned participation in psychological or psychotherapeutic interventions designed to treat an anxiety disorder during the course of the clinical trial
  • Participation in any other clinical trial within 90 days prior to the screening period
  • Lack of willingness to cooperate on the part of the patient
  • Other reasons that, in the opinion of the investigator, prevent the patient from participating in the study or pose an unreasonable risk to the patient

Withdrawal Criteria:

  • Patient's desire to stop participating in the study (withdrawal of informed consent) Each patient has the right to stop participating in the study at any time without giving a reason. Withdrawal from the study will not affect the medical care provided to the patient in the future.
  • A decision by the research physician that the patient should be excluded is in the patient's own best interest
  • Patient refuses to cooperate with the investigator or is undisciplined
  • Causes/occurrence of situations during the study that threaten patient safety (e.g., hypersensitivity reactions, SAE, etc.)
  • Inclusion of a patient in the study with inclusion/inclusion criteria not met (prior to randomization)
  • Significant violation of the treatment regimen A significant violation is defined as a) skipping study drug/placebo for 2 consecutive full days or more, or b) taking, in total, < 80% or >120% of the full course (full course = 168 pills)
  • Positive pregnancy test
  • Confirmed diagnosis of COVID-19
  • Occurrence in the course of the study of other reasons that prevent the study according to the protocol
  • Death of a patient

Treatment and study plan

Ranquilon

Drug

Two 1 mg tablets 3 times per day for 28 days

Other names: GB-115, 6-phenylhexanoyl)glycyl-L-tryptophan amide

Placebo

Drug

Two tablets 3 times per day for 28 days

Primary outcomes

  1. Change in patient status on the Hamilton Anxiety Rating Scale (HARS): Percentage of patients with a significant, i.e., 50% or greater reduction from baseline, in HARS anxiety levels on Day 29 ± 1

    Time frame: Day 29 ± 1 of the study

    HARS scale includes 14 items, each of which is rated on the Likken scale. Of these, 13 items relate to the manifestation of anxiety in daily life, 14 items relate to the manifestation of anxiety during examinations. The sum of the scores may range from 0 to 56, with scores 0 to 7 corresponding to the absence of anxiety, 8 to 17 to the presence of symptoms of anxiety disorder, 18 to 24 to moderate severity of anxiety disorder, and 25 to 56 to severe severity of anxiety disorder.

Secondary outcomes

  1. Proportion of patients with a significant, i.e., 50% or greater reduction in HARS anxiety level on Day 15 ± 1 (Visit 2)

    Time frame: Day 15 ± 1 of the study

    HARS scale includes 14 items, each of which is rated on the Likken scale. Of these, 13 items relate to the manifestation of anxiety in daily life, 14 items relate to the manifestation of anxiety during examinations. The sum of the scores may range from 0 to 56, with scores 0 to 7 corresponding to the absence of anxiety, 8 to 17 to the presence of symptoms of anxiety disorder, 18 to 24 to moderate severity of anxiety disorder, and 25 to 56 to severe severity of anxiety disorder.

  2. Change in HARS anxiety level on Day 15 ± 1 (Visit 2) and Day 29 ± 1 (Visit 3) compared to baseline

    Time frame: Day 15 ± 1 and Day 29 ± 1 of the study

    HARS scale includes 14 items, each of which is rated on the Likken scale. Of these, 13 items relate to the manifestation of anxiety in daily life, 14 items relate to the manifestation of anxiety during examinations. The sum of the scores may range from 0 to 56, with scores 0 to 7 corresponding to the absence of anxiety, 8 to 17 to the presence of symptoms of anxiety disorder, 18 to 24 to moderate severity of anxiety disorder, and 25 to 56 to severe severity of anxiety disorder.

  3. Proportion of patients with HARS anxiety scores reduced to 17 or less on Day 15 ± 1 (Visit 2) and Day 29 ± 1 (Visit 3)

    Time frame: Day 15 ± 1 and Day 29 ± 1 of the study

    HARS scale includes 14 items, each of which is rated on the Likken scale. Of these, 13 items relate to the manifestation of anxiety in daily life, 14 items relate to the manifestation of anxiety during examinations. The sum of the scores may range from 0 to 56, with scores 0 to 7 corresponding to the absence of anxiety, 8 to 17 to the presence of symptoms of anxiety disorder, 18 to 24 to moderate severity of anxiety disorder, and 25 to 56 to severe severity of anxiety disorder.

  4. Time to decrease the HARS anxiety level to a score of 17 or less

    Time frame: Screening, Day 15 ± 1, Day 29 ± 1 of the study, the end of the study (Day 44 ± 1) or an early termination visit, whichever came first

    HARS scale includes 14 items, each of which is rated on the Likken scale. Of these, 13 items relate to the manifestation of anxiety in daily life, 14 items relate to the manifestation of anxiety during examinations. The sum of the scores may range from 0 to 56, with scores 0 to 7 corresponding to the absence of anxiety, 8 to 17 to the presence of symptoms of anxiety disorder, 18 to 24 to moderate severity of anxiety disorder, and 25 to 56 to severe severity of anxiety disorder.

  5. Proportion of patients with significant and marked improvement as assessed by the physician (Clinical Global Impression - improvement (CGI-i) score 1 or 2) at Day 15 ± 1 (Visit 2) and Day 29 ± 1 (Visit 3)

    Time frame: Day 15 ± 1 and Day 29 ± 1 of the study

    The Clinical Global Impression Scale (CGI) includes two subscales: one for severity of symptoms and one for progression of symptoms with treatment. The first subscale is called Clinical Global Impression - severity (CGI-s) and the second subscale is Clinical Global Impression - improvement (CGI-i). CGI-s includes scores from 0 (healthy) to 7 (very severe); CGI-i includes scores from 1 (marked improvement) to 7 (marked deterioration)

  6. Proportion of patients with a CGI-s score of 1 or 2 as assessed by the physician (healthy or borderline disorder) on Day 15 ± 1 (Visit 2) and Day 29 ± 1 (Visit 3)

    Time frame: Day 15 ± 1 and Day 29 ± 1 of the study

    The Clinical Global Impression Scale (CGI) includes two subscales: one for severity of symptoms and one for progression of symptoms with treatment. The first subscale is called Clinical Global Impression - severity (CGI-s) and the second subscale is Clinical Global Impression - improvement (CGI-i). CGI-s includes scores from 0 (healthy) to 7 (very severe); CGI-i includes scores from 1 (marked improvement) to 7 (marked deterioration)

  7. Time to significant or marked improvement - achieving a score of 1 or 2 on the CGI-i scale

    Time frame: Screening, Day 15 ± 1, Day 29 ± 1 of the study, or an early termination visit, whichever came first

    The Clinical Global Impression Scale (CGI) includes two subscales: one for severity of symptoms and one for progression of symptoms with treatment. The first subscale is called Clinical Global Impression - severity (CGI-s) and the second subscale is Clinical Global Impression - improvement (CGI-i). CGI-s includes scores from 0 (healthy) to 7 (very severe); CGI-i includes scores from 1 (marked improvement) to 7 (marked deterioration)

  8. Time to decrease in severity of condition to 2 points or to 1 point or CGI-s scale

    Time frame: Screening, Day 15 ± 1, Day 29 ± 1 of the study, the end of the study (Day 44 ± 1) or an early termination visit, whichever came first

    The Clinical Global Impression Scale (CGI) includes two subscales: one for severity of symptoms and one for progression of symptoms with treatment. The first subscale is called Clinical Global Impression - severity (CGI-s) and the second subscale is Clinical Global Impression - improvement (CGI-i). CGI-s includes scores from 0 (healthy) to 7 (very severe); CGI-i includes scores from 1 (marked improvement) to 7 (marked deterioration)

  9. Absolute value of the patient's CGI-i score by Days 15 ± 1 (Visit 2) and 29 ± 1 (Visit 3)

    Time frame: Day 15 ± 1 and Day 29 ± 1 of the study

    The Clinical Global Impression Scale (CGI) includes two subscales: one for severity of symptoms and one for progression of symptoms with treatment. The first subscale is called Clinical Global Impression - severity (CGI-s) and the second subscale is Clinical Global Impression - improvement (CGI-i). CGI-s includes scores from 0 (healthy) to 7 (very severe); CGI-i includes scores from 1 (marked improvement) to 7 (marked deterioration)

  10. Change in patient severity on the CGI-s scale by Days 15 ± 1 (Visit 2) and 29 ± 1 (Visit 3) compared to baseline

    Time frame: Day 15 ± 1 and Day 29 ± 1 of the study

    The Clinical Global Impression Scale (CGI) includes two subscales: one for severity of symptoms and one for progression of symptoms with treatment. The first subscale is called Clinical Global Impression - severity (CGI-s) and the second subscale is Clinical Global Impression - improvement (CGI-i). CGI-s includes scores from 0 (healthy) to 7 (very severe); CGI-i includes scores from 1 (marked improvement) to 7 (marked deterioration)

  11. Change in the Multidimensional Fatigue Fatigue Inventory (MFI-20) total score on Day 15 ± 1 (Visit 2) and 29 ± 1 (Visit 3) compared to baseline

    Time frame: Day 15 ± 1 and Day 29 ± 1 of the study

    The Multidimensional Fatigue Fatigue Inventory (MFI-20) provides a subjective quantitative assessment of the overall severity of asthenia and its various aspects. This scale consists of 20 items reflecting the main components of asthenic syndrome, such as: general asthenia, physical asthenia, mental asthenia, decreased activity and decreased motivation. The patient was given an opportunity to rate the mentioned items to his/her condition on a five-point scale. The score of the scale is the sum of the points of its individual constituent items and can vary in the range from 5 to 25 points. Normally, the total number of points should not exceed 30. If the total score on one of the subscales was higher than 12, this could be a preliminary ground for classifying the condition as an asthenic syndrome

  12. Time to decrease the MFI-20 cumulative score to 30 points or less

    Time frame: Screening, Day 15 ± 1, Day 29 ± 1 of the study, or an early termination visit, whichever came first

    The Multidimensional Fatigue Fatigue Inventory (MFI-20) provides a subjective quantitative assessment of the overall severity of asthenia and its various aspects. This scale consists of 20 items reflecting the main components of asthenic syndrome, such as: general asthenia, physical asthenia, mental asthenia, decreased activity and decreased motivation. The patient was given an opportunity to rate the mentioned items to his/her condition on a five-point scale. The score of the scale is the sum of the points of its individual constituent items and can vary in the range from 5 to 25 points. Normally, the total number of points should not exceed 30. If the total score on one of the subscales was higher than 12, this could be a preliminary ground for classifying the condition as an asthenic syndrome

  13. Time to decrease the MFI-20 cumulative score by 25% and 50% from baseline

    Time frame: Screening, Day 15 ± 1, Day 29 ± 1 of the study, or an early termination visit, whichever came first

    The Multidimensional Fatigue Fatigue Inventory (MFI-20) provides a subjective quantitative assessment of the overall severity of asthenia and its various aspects. This scale consists of 20 items reflecting the main components of asthenic syndrome, such as: general asthenia, physical asthenia, mental asthenia, decreased activity and decreased motivation. The patient was given an opportunity to rate the mentioned items to his/her condition on a five-point scale. The score of the scale is the sum of the points of its individual constituent items and can vary in the range from 5 to 25 points. Normally, the total number of points should not exceed 30. If the total score on one of the subscales was higher than 12, this could be a preliminary ground for classifying the condition as an asthenic syndrome

  14. Proportion of patients with a 25% reduction in MFI-20 total score on Day 15 ± 1 (Visit 2) and Day 29 ± 1 (Visit 3) from baseline

    Time frame: Day 15 ± 1 and Day 29 ± 1

    The Multidimensional Fatigue Fatigue Inventory (MFI-20) provides a subjective quantitative assessment of the overall severity of asthenia and its various aspects. This scale consists of 20 items reflecting the main components of asthenic syndrome, such as: general asthenia, physical asthenia, mental asthenia, decreased activity and decreased motivation. The patient was given an opportunity to rate the mentioned items to his/her condition on a five-point scale. The score of the scale is the sum of the points of its individual constituent items and can vary in the range from 5 to 25 points. Normally, the total number of points should not exceed 30. If the total score on one of the subscales was higher than 12, this could be a preliminary ground for classifying the condition as an asthenic syndrome

  15. Proportion of patients with a 50% reduction in MFI-20 total score on Day 15 ± 1 (Visit 2) and Day 29 ± 1 (Visit 3) from baseline

    Time frame: Day 15 ± 1 and Day 29 ± 1

    The Multidimensional Fatigue Fatigue Inventory (MFI-20) provides a subjective quantitative assessment of the overall severity of asthenia and its various aspects. This scale consists of 20 items reflecting the main components of asthenic syndrome, such as: general asthenia, physical asthenia, mental asthenia, decreased activity and decreased motivation. The patient was given an opportunity to rate the mentioned items to his/her condition on a five-point scale. The score of the scale is the sum of the points of its individual constituent items and can vary in the range from 5 to 25 points. Normally, the total number of points should not exceed 30. If the total score on one of the subscales was higher than 12, this could be a preliminary ground for classifying the condition as an asthenic syndrome

  16. Proportion of patients with a decrease in their MFI-20 cumulative score to 30 on Day 15 ± 1 (Visit 2) and Day 29 ± 1 (Visit 3)

    Time frame: Day 15 ± 1 and Day 29 ± 1

    The Multidimensional Fatigue Fatigue Inventory (MFI-20) provides a subjective quantitative assessment of the overall severity of asthenia and its various aspects. This scale consists of 20 items reflecting the main components of asthenic syndrome, such as: general asthenia, physical asthenia, mental asthenia, decreased activity and decreased motivation. The patient was given an opportunity to rate the mentioned items to his/her condition on a five-point scale. The score of the scale is the sum of the points of its individual constituent items and can vary in the range from 5 to 25 points. Normally, the total number of points should not exceed 30. If the total score on one of the subscales was higher than 12, this could be a preliminary ground for classifying the condition as an asthenic syndrome

  17. Change in Spielberger personality anxiety level on Day 15 ± 1 (Visit 2) and Day 29 ± 1 (Visit 3) compared to baseline

    Time frame: Day 15 ± 1 and Day 29 ± 1

    The Spielberger Questionnaire includes a series of statements describing personal and situational anxiety, the answers to which are scored from 1 (least severe or prolonged) to 4 (most severe or prolonged). The patient reads the statements and independently chooses the most appropriate frequency for each statement. When analyzing the results of the self-assessment, you should keep in mind that the overall total for each of the subscales may range from 20 to 80 points. The higher the total score, the higher the level of anxiety (situational or personal).

  18. Change in situational anxiety levels on the Spielberger questionnaire on Day 15 ± 1 (Visit 2) and Day 29 ± 1 (Visit 3) compared to baseline

    Time frame: Day 15 ± 1 and Day 29 ± 1

    The Spielberger Questionnaire includes a series of statements describing personal and situational anxiety, the answers to which are scored from 1 (least severe or prolonged) to 4 (most severe or prolonged). The patient reads the statements and independently chooses the most appropriate frequency for each statement. When analyzing the results of the self-assessment, you should keep in mind that the overall total for each of the subscales may range from 20 to 80 points. The higher the total score, the higher the level of anxiety (situational or personal).

  19. Safety and Tolerability: adverse event (AE) rate

    Time frame: From the date of screening (and signing informed consent form) to the end of the study or to an early termination visit, whichever came first, assessed up to day 44 ± 1 for each participant

    Number and frequency of adverse events (AEs) or serious AEs (SAEs)

  20. Safety and Tolerability: AEs associated with the study drug

    Time frame: From the date of screening (and signing informed consent form) to the end of the study or to an early termination visit, whichever came first, assessed up to day 44 ± 1 for each participant

    Number and frequency of AEs or SAEs associated with the study drug

  21. Safety and Tolerability: treatment discontinuation

    Time frame: From the date of screening (and signing informed consent form) to the end of the study or to an early termination visit, whichever came first, assessed up to day 44 ± 1 for each participant

    Percentage of patients who discontinued treatment due to the occurrence of AEs/SAEs

  22. Safety and Tolerability: vital signs - systolic blood pressure (SBP)

    Time frame: Screening, day 1, day 15, day 29, and day 44 of the study or on the early termination visit, whichever came first, within 44 days of study participation

    SBP, mmHg

  23. Safety and Tolerability: vital signs - diastolic blood pressure (DBP)

    Time frame: Screening, day 1, day 15, day 29, and day 44 of the study or on the early termination visit, whichever came first, within 44 days of study participation

    DBP, mmHg

  24. Safety and Tolerability: vital signs - respiratory rate (RR)

    Time frame: Screening, day 1, day 15, day 29, and day 44 of the study or on the early termination visit, whichever came first, within 44 days of study participation

    RR, breaths per minute

  25. Safety and Tolerability: vital signs - heart rate (HR)

    Time frame: Screening, day 1, day 15, day 29, and day 44 of the study or on the early termination visit, whichever came first, within 44 days of study participation

    HR, beats per minute

  26. Safety and Tolerability: vital signs - body temperature

    Time frame: Screening, day 1, day 15, day 29, and day 44 of the study or on the early termination visit, whichever came first, within 44 days of study participation

    Body temperature, centigrade scale

  27. Safety and Tolerability: physical examination results

    Time frame: Screening, day 1, day 15, day 29, and day 44 of the study or on the early termination visit, whichever came first, within 44 days of study participation

    Physical examination will follow the general rules of internal medicine: general examination, examination of mucous membranes and skin, including palpation of lymph nodes, evaluation of the musculoskeletal system, palpation, percussion, and auscultation of the main organ systems (cardiovascular, respiratory, digestive, and urinary systems) will be performed sequentially

  28. Safety and Tolerability: 12-lead electrocardiogram (ECG) - heart rate

    Time frame: Screening, day 29, or on the early termination visit, whichever came first, within 44 days of study participation

    12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: heart rate (beats per minute)

  29. Safety and Tolerability: 12-lead electrocardiogram (ECG) - PQ interval

    Time frame: Screening, day 29, or on the early termination visit, whichever came first, within 44 days of study participation

    12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: PQ interval (ms)

  30. Safety and Tolerability: 12-lead electrocardiogram (ECG) - QRS complex

    Time frame: Screening, day 29, or on the early termination visit, whichever came first, within 44 days of study participation

    12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: QRS complex (ms)

  31. Safety and Tolerability: 12-lead electrocardiogram (ECG) - corrected QT interval (QTc)

    Time frame: Screening, day 29, or on the early termination visit, whichever came first, within 44 days of study participation

    12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: QTc (ms)

  32. Safety and Tolerability: complete blood count - hemoglobin

    Time frame: Screening, Day 29 or the early termination visit, whichever came first, within 44 days of study participation

    Hemoglobin, g/dL

  33. Safety and Tolerability: complete blood count - hematocrit

    Time frame: Screening, Day 29 or the early termination visit, whichever came first, within 44 days of study participation

    Hematocrit, %

  34. Safety and Tolerability: complete blood count - red blood cells

    Time frame: Screening, Day 29 or the early termination visit, whichever came first, within 44 days of study participation

    Red blood cells, 10^6/uL

  35. Safety and Tolerability: complete blood count - white blood cells

    Time frame: Screening, Day 29 or the early termination visit, whichever came first, within 44 days of study participation

    White blood cells, 10^3/uL

  36. Safety and Tolerability: complete blood count - platelets

    Time frame: Screening, Day 29 or the early termination visit, whichever came first, within 44 days of study participation

    Platelets, 10^3/uL

  37. Safety and Tolerability: complete blood count - erythrocyte sedimentation rate

    Time frame: Screening, Day 29 or the early termination visit, whichever came first, within 44 days of study participation

    Erythrocyte sedimentation rate, mm per hour

  38. Safety and Tolerability: complete blood count - lymphocytes

    Time frame: Screening, Day 29 or the early termination visit, whichever came first, within 44 days of study participation

    Lymphocytes, %

  39. Safety and Tolerability: complete blood count - eosinophils

    Time frame: Screening, Day 29 or the early termination visit, whichever came first, within 44 days of study participation

    Eosinophils, %

  40. Safety and Tolerability: complete blood count - monocytes

    Time frame: Screening, Day 29 or the early termination visit, whichever came first, within 44 days of study participation

    Monocytes, %

  41. Safety and Tolerability: complete blood count - basophils

    Time frame: Screening, Day 29 or the early termination visit, whichever came first, within 44 days of study participation

    Basophils, %

  42. Safety and Tolerability: complete blood count - neutrophils

    Time frame: Screening, Day 29 or the early termination visit, whichever came first, within 44 days of study participation

    Neutrophils, % (segmented and stab)

  43. Safety and Tolerability: blood test results - total cholesterol

    Time frame: Screening, Day 29 or the early termination visit, whichever came first, within 44 days of study participation

    Total cholesterol in blood serum, mmol/L

  44. Safety and Tolerability: blood test results - total protein

    Time frame: Screening, Day 29 or the early termination visit, whichever came first, within 44 days of study participation

    Total protein in blood serum, g/L

  45. Safety and Tolerability: blood test results - glucose

    Time frame: Screening, Day 29 or the early termination visit, whichever came first, within 44 days of study participation

    Glucose in blood serum, mmol/L

  46. Safety and Tolerability: blood test results - creatinine

    Time frame: Screening, Day 29 or the early termination visit, whichever came first, within 44 days of study participation

    Creatinine in blood serum, umol/L

  47. Safety and Tolerability: blood test results - alanine transaminase (ALT)

    Time frame: Screening, Day 29 or the early termination visit, whichever came first, within 44 days of study participation

    ALT in blood serum, U/L

  48. Safety and Tolerability: blood test results - aspartate transaminase (AST)

    Time frame: Screening, Day 29 or the early termination visit, whichever came first, within 44 days of study participation

    AST in blood serum, U/L

  49. Safety and Tolerability: blood test results - total bilirubin

    Time frame: Screening, Day 29 or the early termination visit, whichever came first, within 44 days of study participation

    Total bilirubin in blood serum, umol/L

  50. Safety and Tolerability: blood test results - direct bilirubin

    Time frame: Screening, Day 29 or the early termination visit, whichever came first, within 44 days of study participation

    Direct bilirubin in blood serum, umol/L

  51. Safety and Tolerability: blood test results - alkaline phosphatase (ALP)

    Time frame: Screening, Day 29 or the early termination visit, whichever came first, within 44 days of study participation

    ALP in blood serum, U/L

  52. Safety and Tolerability: blood test results - urea

    Time frame: Screening, Day 29 or the early termination visit, whichever came first, within 44 days of study participation

    Urea in blood serum, mmol/L

  53. Safety and Tolerability: urinalysis - color

    Time frame: Screening, Day 29 or the early termination visit, whichever came first, within 44 days of study participation

    Color of the urine (yellow, brown, etc.)

  54. Safety and Tolerability: urinalysis - transparency

    Time frame: Screening, Day 29 or the early termination visit, whichever came first, within 44 days of study participation

    Transparency of the urine (transparent/cloudy)

  55. Safety and Tolerability: urinalysis - specific gravity

    Time frame: Screening, Day 29 or the early termination visit, whichever came first, within 44 days of study participation

    Specific gravity of the urine

  56. Safety and Tolerability: urinalysis - pH

    Time frame: Screening, Day 29 or the early termination visit, whichever came first, within 44 days of study participation

    pH of the urine

  57. Safety and Tolerability: urinalysis - glucose

    Time frame: Screening, Day 29 or the early termination visit, whichever came first, within 44 days of study participation

    Glucose in the urine (mmol/L)

  58. Safety and Tolerability: urinalysis - protein

    Time frame: Screening, Day 29 or the early termination visit, whichever came first, within 44 days of study participation

    Protein in the urine (g/L)

  59. Safety and Tolerability: urinalysis - ketones

    Time frame: Screening, Day 29 or the early termination visit, whichever came first, within 44 days of study participation

    Ketones in the urine (mmol/L)

  60. Safety and Tolerability: urinalysis - urobilinogen

    Time frame: Screening, Day 29 or the early termination visit, whichever came first, within 44 days of study participation

    Urobilinogen in the urine (umol/L)

Sponsors and collaborators

Lead sponsor

Valenta Pharm JSC

Industry

Registry information

Official study title

A Double-blind, Randomized, Placebo-controlled, Multicenter Phase III Clinical Trial to Examine the Clinical Efficacy and Safety of Ranquilon, 1 mg Tablets in Patients With Anxiety in Neurasthenia and Adjustment Disorders

Important dates

Study start
2022
Primary completion
2022
Study completion
2023
First posted
Oct 19, 2022
Registry last updated
Jul 27, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.